Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

Presentation THT 2026

How Will Guideline Committees View Results From RWE Trials?

Presenter: Paul Heidenrich

March 04, 2026

Presentation THT 2026

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Presenter: Tor Biering-Sørensen

March 04, 2026

Presentation THT 2026

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Presenter: Robert W. Yeh

March 04, 2026

Presentation THT 2026

Time for a Separate Guideline Path for HF Devices?

Presenter: Javed Butler

March 04, 2026

Presentation THT 2026

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

Presenter: James Januzzi

March 04, 2026

Presentation THT 2026

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Presenter: Gregg W. Stone

March 04, 2026

Presentation THT 2026

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

Presenter: John A. Spertus

March 04, 2026

Presentation THT 2026

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Presenter: JoAnn Lindenfeld

March 04, 2026

Presentation THT 2026

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Presenter: Beth A. Davison

March 04, 2026

Presentation THT 2026

Impact of Left Atrial Appendage Closure on Clinical Outcomes In Patients with Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials

Presenter: Mark Darkwah

March 03, 2026

Presentation THT 2026

Optimal Mean Arterial Pressure, Time in Target Range, and Outcomes in HeartMate 3 Recipients: Pooled Individual-Patient Data from MOMENTUM-3 and ARIES-HM3 Trials

Presenter: Nelson Wang

March 03, 2026

Presentation THT 2025

Imaging for Assessing Heart Muscle Disease: State of the Art for Trial Endpoints, Drug Development and Clinical Practice

Presenter: Jonathan Weinsaft

February 12, 2025

Presentation THT 2025

AI Echo's Potential to Transform HF Management

Presenter: Carolyn Lam

February 12, 2025

Presentation THT 2025

HFpEF: Can Image Phenotyping Help for Prognostication and Therapy DEevelopment

Presenter: Jonathan Cunningham

February 12, 2025

Presentation THT 2025

Use of AI-Based Automated Detection of Clinically Significant VHD From Echocardiography

Presenter: Akhil Narang

February 12, 2025

Presentation THT 2025

Lessons Learned From RESHAPE-HF-2: An Imager's Perspective

Presenter: Ralph von Bardeleben

February 12, 2025

Presentation THT 2025

Strengths and Weaknesses of VHD Quantitation in Clinical Research and Daily Practice

Presenter: Rebecca Hahn

February 12, 2025

Presentation THT 2025

Challenges in Designing Collaborative Clinical Therapeutic Trials in HT

Presenter: Jeffrey Teuteberg

February 12, 2025

Presentation THT 2025

Ventricular Remodeling as an Endpoint for HF Trials: Methods, Comparative Precision, Real-World Applicability

Presenter: Joao Cavalcante

February 12, 2025

Presentation THT 2025

When to Use a Noninvasive Device That Remove Fluid From the Extracellular Space

Presenter: Daniel Bensimhon

February 12, 2025

Advertisement

How Will Guideline Committees View Results From RWE Trials?

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Time for a Separate Guideline Path for HF Devices?

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Impact of Left Atrial Appendage Closure on Clinical Outcomes In Patients with Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials

Optimal Mean Arterial Pressure, Time in Target Range, and Outcomes in HeartMate 3 Recipients: Pooled Individual-Patient Data from MOMENTUM-3 and ARIES-HM3 Trials

Imaging for Assessing Heart Muscle Disease: State of the Art for Trial Endpoints, Drug Development and Clinical Practice

AI Echo's Potential to Transform HF Management

HFpEF: Can Image Phenotyping Help for Prognostication and Therapy DEevelopment

Use of AI-Based Automated Detection of Clinically Significant VHD From Echocardiography

Lessons Learned From RESHAPE-HF-2: An Imager's Perspective

Strengths and Weaknesses of VHD Quantitation in Clinical Research and Daily Practice

Challenges in Designing Collaborative Clinical Therapeutic Trials in HT

Ventricular Remodeling as an Endpoint for HF Trials: Methods, Comparative Precision, Real-World Applicability

When to Use a Noninvasive Device That Remove Fluid From the Extracellular Space

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content